Clinical Trial Detail

NCT ID NCT04332874
Title A Study of Pembrolizumab Plus Local Chemotherapy Using Isolated Limb Infusion (ILI) for Patients With Sarcoma in the Arm or Leg
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Memorial Sloan Kettering Cancer Center
Indications

alveolar soft part sarcoma

sarcoma

myxofibrosarcoma

Therapies

Pembrolizumab

Age Groups: senior adult

No variant requirements are available.